Addition of ipatasertib to abiraterone benefits certain patients with metastatic CRPC

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 20 / Springer Healthcare

Addition of ipatasertib to abiraterone benefits certain patients with metastatic CRPC

Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Oncology Prostate Cancer Urogenital Cancer ESMO-2020

Description

Christopher Sweeney reports on the IPATential150 trial demonstrating the potential of combining the AKT inhibitor ipatasertib with abiraterone in metastatic castration-resistant prostate cancer patients with PTEN loss.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.